Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling

Nature Communications

Volumn 6, Issue , 2015, Pages

  Chandler, Ronald L ^a,b   Damrauer, Jeffrey S ^a,b   Raab, Jesse R ^a,b   Schisler, Jonathan C ^a   Wilkerson, Matthew D ^a,b   Didion, John P ^a,b   Starmer, Joshua ^a,b   Serber, Daniel ^a,b   Yee, Della ^a,b   Xiong, Jessie ^b   Darr, David B ^b   De Villena, Fernando Pardo Manuel ^a,b   Kim, William Y ^a,b   Magnuson, Terry ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT RICH INTERACTIVE DOMAIN CONTAINING PROTEIN 1A; BUPARLISIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT; PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VCAN PROTEIN; ARID1A PROTEIN, MOUSE; CYTOKINE; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR;

CYTOLOGY; GENE EXPRESSION; INHIBITION; MUTATION; RODENT; SURVIVAL; TUMOR;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL AGGREGATION; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EMBRYONIC STEM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXON; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENOTYPE; HAPLOINSUFFICIENCY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOXP SITE; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA, CLEAR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL SURVIVAL; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; INFLAMMATION; METABOLISM; MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR GENE;

MUS;

ADENOCARCINOMA, CLEAR CELL; ALLELES; ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEMALE; GENES, TUMOR SUPPRESSOR; HAPLOINSUFFICIENCY; INFLAMMATION; INTERLEUKIN-6; MICE, INBRED C57BL; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84923102594     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7118     Document Type: Article

References (70)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Adashi, E. Y. & Leung, P. C. K. The Ovary 591-602 (Elsevier Academic Press, 2004).
3. Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751-765 (2013).
4. Vigano, P., Somigliana, E., Chiodo, I., Abbiati, A. & Vercellini, P. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: A critical analysis. Hum. Reprod. Update 12, 77-89 (2006).
5. Ness, R. B. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. Am. J. Obstet. Gynecol. 189, 280-294 (2003).
6. Kurman, R. J. & Shih, I. e. M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am. J. Surg. Pathol. 34, 433-443 (2010).
7. Dinulescu, D. M. et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11, 63-70 (2005).
8. Wu, R. et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11, 321-333 (2007).
9. Glasspool, R. M. & McNeish, I. A. Clear cell carcinoma of ovary and uterus. Curr. Oncol. Rep. 15, 566-572 (2013).
10. Cho, K. R. & Shih, I. e. M. Ovarian cancer. Annu. Rev. Pathol. 4, 287-313 (2009).
11. Tan, D. S., Miller, R. E. & Kaye, S. B. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br. J. Cancer 108, 1553-1559 (2013).
12. Kobayashi, H. Ovarian cancer in endometriosis: Epidemiology, natural history, and clinical diagnosis. Int. J. Clin. Oncol. 14, 378-382 (2009).
13. Jimbo, H. et al. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 59, 245-250 (1997).
14. Ness, R. B. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. Am. J. Obstet. Gynecol. 189, 280-294 (2003).
15. Itamochi, H., Kigawa, J. & Terakawa, N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 99, 653-658 (2008).
16. Tan, D. S. & Kaye, S. Ovarian clear cell adenocarcinoma: A continuing enigma. J. Clin. Pathol. 60, 355-360 (2007).
17. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
18. Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. New Engl. J. Med. 363, 1532-1543 (2010).
19. Wu, J. N. & Roberts, C. W. ARID1A mutations in cancer: Another epigenetic tumor suppressor? Cancer Discov. 3, 35-43 (2013).
20. Jones, S. et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat. Commun. 5, 5006 (2014).
21. Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592-601 (2013).
22. Wang, X., Haswell, J. R. & Roberts, C. W. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer-mechanisms and potential therapeutic insights. Clin. Cancer Res. 20, 21-27 (2014).
23. Jones, S. et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 33, 100-103 (2012).
24. Chandler, R. L. et al. ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF. Mol. Cell. Biol. 33, 265-280 (2013).
25. Lengyel, E. et al. Epithelial ovarian cancer experimental models. Oncogene 33, 3619-3633 (2014).
26. Guan, B. et al. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J. Natl Cancer Inst. 106 pii: Dju146 (2014).
27. Gao, X. et al. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc. Natl Acad. Sci. USA 105, 6656-6661 (2008).
28. Hayashi, S., Lewis, P., Pevny, L. & McMahon, A. P. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech. Dev. 119 (Suppl 1), S97-S101 (2002).
29. Flesken-Nikitin, A., Choi, K. C., Eng, J. P., Shmidt, E. N. & Nikitin, A. Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63, 3459-3463 (2003).
30. Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681 (2004).
31. Kuo, K. T. et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174, 1597-1601 (2009).
32. Zang, Z. J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012).
33. Yamamoto, S., Tsuda, H., Takano, M., Tamai, S. & Matsubara, O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod. Pathol. 25, 615-624 (2012).
34. Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652-2657 (2008).
35. Adams, J. R. et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 71, 2706-2717 (2011).
36. Kinross, K. M. et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 122, 553-557 (2012).
37. Lowery, W. J. et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int. J. Gynecol. Cancer 22, 9-14 (2012).
38. Offman, S. L. & Longacre, T. A. Clear cell carcinoma of the female genital tract (not everything is as clear as it seems). Adv. Anat. Pathol. 19, 296-312 (2012).
39. Hendrix, N. D. et al. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 66, 1354-1362 (2006).
40. Yamaguchi, K. et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29, 1741-1752 (2010).
41. Yanaihara, N. et al. Cytokine gene expression signature in ovarian clear cell carcinoma. Int. J. Oncol. 41, 1094-1100 (2012).
42. Anglesio, M. S. et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin. Cancer Res. 17, 2538-2548 (2011).
43. Naugler, W. E. & Karin, M. The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109-119 (2008).
44. Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904-910 (2012).
45. Vasudevan, K. M. et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32 (2009).
46. Jia, S. et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776-779 (2008).
47. Ness, R. B. & Cottreau, C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl Cancer Inst. 91, 1459-1467 (1999).
48. Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. New Engl. J. Med. 363, 1532-1543.
49. Samartzis, E. P. et al. Loss of ARID1A/BAF250a-expression in endometriosis: A biomarker for risk of carcinogenic transformation? Mod. Pathol. 25, 885-892 (2012).
50. Wiegand, K. C. et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 224, 328-333.
51. Somigliana, E. et al. Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Hum. Reprod. 19, 1871-1876 (2004).
52. Darai, E., Detchev, R., Hugol, D. & Quang, N. T. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum. Reprod. 18, 1681-1685 (2003).
53. Chang, Q., Daly, L. & Bromberg, J. The IL-6 feed-forward loop: A driver of tumorigenesis. Semin. Immunol. 26, 48-53 (2014).
54. Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineeringbased method for generating conditional knockout mutations. Genome Res. 13, 476-484 (2003).
55. Brachmann, S. M. et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 11, 1747-1757 (2012).
56. Roberts, P. J. et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res. 18, 5290-5303 (2012).
57. Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012).
58. Collaborative Cross Consortium. The genome architecture of the Collaborative Cross mouse genetic reference population. Genetics 190, 389-401 (2012).
59. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910-16915 (2010).
60. Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
61. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
62. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).
63. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
64. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
65. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
66. Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
67. Shepherd, T. G., Theriault, B. L., Campbell, E. J. & Nachtigal, M. W. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat. Protoc. 1, 2643-2649 (2006).
68. Flesken-Nikitin, A. et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495, 241-245 (2013).
69. Inouye, S. et al. Impaired IgG production in mice deficient for heat shock transcription factor 1. J. Biol. Chem. 279, 38701-38709 (2004).
70. Inouye, S. et al. Heat shock transcription factor 1 opens chromatin structure of interleukin-6 promoter to facilitate binding of an activator or a repressor. J. Biol. Chem. 282, 33210-33217 (2007).